| 1 |
mammalian target of rapamycin
(11375 times)
|
Neoplasms
(2144 times)
|
PI3K (1482 times)
AMPK (742 times)
mTORC1 (405 times)
|
1995 Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.
|
| 2 |
mammalian TOR
(33 times)
|
Cell Biology
(9 times)
|
TOR (21 times)
S6K1 (2 times)
TORC1 (2 times)
|
1999 Mammalian TOR controls one of two kinase pathways acting upon nPKCdelta and nPKCepsilon.
|
| 3 |
molecular target of rapamycin
(20 times)
|
Neoplasms
(6 times)
|
PI3K (4 times)
CXCR4 (3 times)
EGFR (3 times)
|
2003 The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
|
| 4 |
mammalian rapamycin target protein
(8 times)
|
Nephrology
(1 time)
|
p-mTOR (2 times)
PI3K (2 times)
RT-PCR (2 times)
|
2017 [Occurrence, diagnosis and treatment of de novo gastrointestinal malignancies after organ transplantation].
|
| 5 |
mechanistic target of rapamycin (serine/threonine kinase)
(5 times)
|
Hematology
(1 time)
|
PI3K (4 times)
AKT (2 times)
ATXN1 (1 time)
|
2014 New function of type I IFN: induction of autophagy.
|
| 6 |
3-kinase-Akt-mechanistic target of rapamycin
(2 times)
|
Pediatrics
(1 time)
|
BCAP (1 time)
ccRCC (1 time)
IL (1 time)
|
2018 Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies.
|
| 7 |
mammalian target of sirolimus
(2 times)
|
Drug Therapy
(1 time)
|
PBL (1 time)
SRL (1 time)
TDM (1 time)
|
2002 Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus.
|
| 8 |
mechanistic (formerly 'mammalian') target of rapamycin
(2 times)
|
Neurology
(1 time)
|
TME (1 time)
|
2016 The mTOR signalling cascade: paving new roads to cure neurological disease.
|
| 9 |
mitochondrial target of rapamycin
(2 times)
|
Molecular Biology
(1 time)
|
AM (1 time)
GSK-3beta (1 time)
IGF-1 (1 time)
|
2011 PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis.
|
| 10 |
molecular target
(2 times)
|
Rheumatology
(1 time)
|
PDB (1 time)
Tfh (1 time)
Th (1 time)
|
2015 Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.
|
| 11 |
mTOR-complex
(2 times)
|
Neurology
(1 time)
|
GBM (2 times)
PI3K (2 times)
EGFR (1 time)
|
2016 PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
|
| 12 |
Akt-mammalian TOR
(1 time)
|
Biochemistry
(1 time)
|
OS (1 time)
|
2014 C6 ceramide sensitizes pemetrexed-induced apoptosis and cytotoxicity in osteosarcoma cells.
|
| 13 |
complex target of rapamycin
(1 time)
|
Rheumatology
(1 time)
|
SLE (1 time)
TSC (1 time)
|
2015 Coincidence of tuberous sclerosis and systemic lupus erythematosus-a case report.
|
| 14 |
downstream target of rapamycin
(1 time)
|
Physiological Phenomena
(1 time)
|
BFR (1 time)
ECC (1 time)
S6K1 (1 time)
|
2015 Blood flow restriction prevents muscle damage but not protein synthesis signaling following eccentric contractions.
|
| 15 |
integrin-mechanistic target of the Rapamycin
(1 time)
|
Cell Biology
(1 time)
|
BMSCs (1 time)
LIPUS (1 time)
|
2017 TGF-beta1-induced chondrogenesis of bone marrow mesenchymal stem cells is promoted by low-intensity pulsed ultrasound through the integrin-mTOR signaling pathway.
|
| 16 |
m Target of Rapamycin
(1 time)
|
Endocrinology
(1 time)
|
3-MA (1 time)
9-CPA (1 time)
9mA (1 time)
|
2015 Monomethylated-adenines potentiate glucose-induced insulin production and secretion via inhibition of phosphodiesterase activity in rat pancreatic islets.
|
| 17 |
M: echanistic T: arget of R: apamycin
(1 time)
|
Neoplasms
(1 time)
|
---
|
2015 Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy.
|
| 18 |
mammalian counterpart of TOR
(1 time)
|
Cell Biology
(1 time)
|
ERK5 (1 time)
TOR (1 time)
|
2008 Integration of protein kinases mTOR and extracellular signal-regulated kinase 5 in regulating nucleocytoplasmic localization of NFATc4.
|
| 19 |
mammalian homolog of target of rapamycin
(1 time)
|
Pharmacology
(1 time)
|
AMPK (1 time)
|
2005 AMPK, the metabolic syndrome and cancer.
|
| 20 |
mammalian homolog of the Saccharomyces cerevisiae target of rapamycin proteins
(1 time)
|
Biotechnology
(1 time)
|
eIF4E (1 time)
FKBP (1 time)
PKCdelta (1 time)
|
2000 Functional interaction between RAFT1/FRAP/mTOR and protein kinase cdelta in the regulation of cap-dependent initiation of translation.
|
| 21 |
Mammalian rapamycin receptor
(1 time)
|
Endocrinology
(1 time)
|
LVH (1 time)
S6K1 (1 time)
SHR (1 time)
|
2021 mTOR inhibitor improves testosterone-induced myocardial hypertrophy in hypertensive rats.
|
| 22 |
mammalian target of mammalian target rapamycin
(1 time)
|
Pharmacology
(1 time)
|
NF-kappaB (1 time)
PKM2 (1 time)
PRAS40 (1 time)
|
2021 Targeting PRAS40: a novel therapeutic strategy for human diseases.
|
| 23 |
mammalian target of rapamycin is an evolutionarily conserved serine-threonine kinase
(1 time)
|
Pharmacology
(1 time)
|
---
|
2009 Effect of rapamycin on cue-induced drug craving in abstinent heroin addicts.
|
| 24 |
mammalian target of rapamycin phosphorylation
(1 time)
|
Genetics, Medical
(1 time)
|
LPS (1 time)
siRNA (1 time)
|
2018 The transcription factor cMaf is targeted by mTOR, and regulates the inflammatory response via the TLR4 signaling pathway.
|
| 25 |
mammalian TOR homologue
(1 time)
|
Biochemistry
(1 time)
|
---
|
1995 TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.
|
| 26 |
mechanism by which a nutrient sensor
(1 time)
|
Science
(1 time)
|
YY1 (1 time)
|
2007 mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex.
|
| 27 |
mechanistic of rapamycin
(1 time)
|
Neurology
(1 time)
|
AMPK (1 time)
miRNAs (1 time)
NCDs (1 time)
|
2016 Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease.
|
| 28 |
mechanistic target of rapamycin as it is known now
(1 time)
|
Neoplasms
(1 time)
|
ASH (1 time)
eIFs (1 time)
HCC (1 time)
|
2017 New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors.
|
| 29 |
mechanistic TOR
(1 time)
|
Cell Biology
(1 time)
|
TOR (1 time)
|
2013 Duration of rapamycin treatment has differential effects on metabolism in mice.
|
| 30 |
menopause, transplantologic age, CSD, previous glomerulonephritis, andmammalian target of rapamycin
(1 time)
|
Transplantation
(1 time)
|
BMD (1 time)
CSD (1 time)
imTOR (1 time)
|
2017 Understanding Bone Damage After Kidney Transplantation: ARetrospective Monocentric Cross Sectional Analysis.
|
| 31 |
metabolic regulator
(1 time)
|
Physiology
(1 time)
|
GOT (1 time)
qRT-PCR (1 time)
TG (1 time)
|
2017 Preventive effect of L-carnitine on the disorder of lipid metabolism and circadian clock of mice subjected to chronic jet-lag.
|
| 32 |
metabolism regulatory gene
(1 time)
|
Reproductive Medicine
(1 time)
|
FDA (1 time)
IMP (1 time)
ROS (1 time)
|
2019 Imperatorin improves invitro porcine embryo development by reducing oxidative stress and autophagy.
|
| 33 |
mitogen-activated protein kinase
(1 time)
|
Environmental Health
(1 time)
|
ER (1 time)
MAPK (1 time)
MPs (1 time)
|
2021 The Kidney-Related Effects of Polystyrene Microplastics on Human Kidney Proximal Tubular Epithelial Cells HK-2 and Male C57BL/6 Mice.
|
| 34 |
modification of an immunosuppressive regimen with introduction of rapamycin
(1 time)
|
Nephrology
(1 time)
|
CNIs (1 time)
SCC (1 time)
|
2021 Rapamycin Inhibitors for Eye Squamous Cell Carcinoma after Renal Transplantation: A Case Report.
|
| 35 |
modulation of key molecules of the rapamycin
(1 time)
|
Biomedical Research
(1 time)
|
ANOVA (1 time)
PI3K (1 time)
PTEN (1 time)
|
2020 Wubeizi Ointment Suppresses Keloid Formation through Modulation of the mTOR Pathway.
|
| 36 |
more effective than the rapamycin
(1 time)
|
Biomedical Engineering
(1 time)
|
PPARalpha (1 time)
TSC (1 time)
Vif (1 time)
|
2010 Systems analysis of small signaling modules relevant to eight human diseases.
|
| 37 |
most patients receive sunitinib or amammalian target of rapamycin
(1 time)
|
Neoplasms
(1 time)
|
DCR (1 time)
mpRCC (1 time)
OS (1 time)
|
2021 Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales).
|
| 38 |
MS and for drug and target protein
(1 time)
|
Pharmacology
(1 time)
|
---
|
2018 Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings.
|
| 39 |
mTOR Complex; RAS, Rat sarcoma; RAF, rapidly accelerated fibrosarcoma
(1 time)
|
Hematology
(1 time)
|
MB (1 time)
|
2015 Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex: Case Description and Molecular Characterization of the Tumor.
|
| 40 |
muscle protein synthesis
(1 time)
|
Nutritional Sciences
(1 time)
|
MAFbx (1 time)
MuRF-1 (1 time)
|
2014 Whey protein modifies gene expression related to protein metabolism affecting muscle weight in resistance-exercised rats.
|
| 41 |
phosphatidylinositol-3-kinase-AKT-mechanistic target of rapamycin
(1 time)
|
Biology
(1 time)
|
endo-lysosomes (1 time)
LPS (1 time)
mTORC1 (1 time)
|
2019 Enhanced translation expands the endo-lysosome size and promotes antigen presentation during phagocyte activation.
|
A Search Service for Abbreviation / Long Form